Topic: mergers and acquisitions
Johnson & Johnson's unit Apsis acquired French robot-assisted surgery company Orthotaxy for an undisclosed price.
The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
The takeover gives Roche ownership of the cancer software and real-world evidence that turned GV-backed Flatiron into a rising star.
Astellas has bought out a U.S. biotech that wants to ensure cell therapy products aren’t rejected by a patient’s immune system.
Charles River Laboratories snatches up nonclinical CRO MPI Research for $800 million in cash.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.
After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.
Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month.
Allergan, flush from a series of small and midsized deals over the past 18 months, is reported to be seeking a buyout of women’s health company KaNDy Therapeutics.
China’s Shanghai Pharma is planning to open an R&D unit in San Diego as part of an international expansion drive that could also include acquisitions in the U.S. and Europe.